426 results about "Radical radiotherapy" patented technology

Techniques for adjusting radiotherapy treatment for a patient in real time are provided. The techniques include operations comprising: obtaining, during delivery of a radiotherapy treatment fraction to a patient, one or more images of the patient at a first rate; generating patient motion information at a second rate based on the one or more images obtained at the first rate; receiving, during delivery of the radiotherapy treatment fraction, radiotherapy treatment device settings at a third rate; computing, during delivery of the radiotherapy treatment fraction, dose delivered to the patient with a first level of accuracy based on the generated patient motion information and the radiotherapy treatment device settings; and determining, during delivery of the radiotherapy treatment fraction, a real-time measure of accumulated dose delivered to the patient with a second greater level of accuracy than the first level of accuracy using one or more prior dose computations.

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.

Described herein are systems and methods for positioning a radiation source with respect to one or more regions of interest in a coordinate system. Such systems and methods may be used in emission guided radiation therapy (EGRT) for the localized delivery of radiation to one or more patient tumor regions. These systems comprise a gantry movable about a patient area, where a plurality of positron emission detectors, a radiation source are arranged movably on the gantry, and a controller. The controller is configured to identify a coincident positron annihilation emission path and to position the radiation source to apply a radiation beam along the identified emission path. The systems and methods described herein can be used alone or in conjunction with surgery, chemotherapy, and / or brachytherapy for the treatment of tumors.

Disclosed are a radiotherapy system and a treatment plan generation method therefor. The radiotherapy system includes a beam irradiation device, a treatment planning module and a control module. The beam irradiation device generates a beam for treatment and irradiates same to a body to be irradiated to form an irradiated site, the treatment planning module generates a treatment plan on the basis of parameters of the beam for treatment and medical image data of the irradiated site, and the control module retrieves a treatment plan corresponding to said body from the treatment planning module and controls the beam irradiation device to sequentially irradiate said body according to at least two irradiation angles determined according to the treatment plan generation method and the irradiation time corresponding to each irradiation angle.

The invention relates to the technical field of radiation therapy, in particular to a boron neutron capture therapy beam shaping device and a boron neutron capture therapy system. The beam shaping device for boron neutron capture therapy is used for beam shaping of a DT neutron tube generator. The interior of the beam shaping device is provided with a particle beam channel, and the particle beam channel is used for generating an initial neutron source through an incident proton beam. The beam shaping device comprises a value-added layer, a moderator, a filter layer, a reflecting layer, a collimator and a shielding layer, wherein the value-added layer, the moderator, the filter layer and the collimator are sequentially arranged from a target material to an outlet. And the axes of the particle beam channel, the value-added layer, the moderator and the collimator coincide. According to the beam shaping device, 14Mev high-energy neutrons from the DT neutron tube generator are shaped into hot / slow neutron beams meeting the BNCT treatment requirements, and impurities of fast neutrons and gamma rays are reduced to the maximum extent, so that the dosage precision and biological selectivity of treatment are effectively improved.

The present application relates to a radiotherapy apparatus for delivering radiation to a subject. The apparatus comprises a source of radiation configured to rotate about an isocenter and emit radiation in a radiation plane containing said isocentre. The apparatus also comprises a subject support surface including a portion configured to be located substantially at the isocenter. The subject support surface comprises a subject support surface rotation mechanism configured to rotate the subject support surface about an axis of rotation parallel to and spaced from an axis that passes through the isocenter. The subject support surface also comprises a first section configured to move from a first position to a second position along at least one of a longitudinal and lateral direction. The apparatus also comprises a processor configured to control the longitudinal and / or lateral movement of the first section as a function of the rotation of the subject support surface to maintain the portion of the subject support surface substantially at the isocenter.

By using the Al module, the method of the present invention calculates, i.e. predicts, the dependency Ci (pi) of a radiotherapy (RT) quality criterion C, from an adjustment of such a radiotherapy planning parameter pi. In this way, the decision making process in RT treatment plan optimization is streamlined by prediction of promising settings of one or more radiotherapy planning parameters p, before the actual time intensive iterative optimization process is carried out. This is achieved by applying an Al module, which has been trained to predict the specific behaviour of the dose optimization algorithm, i.e. the optimizer, with respect to geometric patient data, dose prescription and treatment indication data. Thus, a computer-implemented medical method of predicting a dependency Ci (pi) of a radiotherapy (RT) quality criterion Ci from an adjustment of a radiotherapy planning parameter p, is presented. The method comprises the following steps of providing geometric patient data geometrically describing an area of a patient, which is to be irradiated according to a radiotherapy treatment plan (step S1), providing dose prescription data and treatment indication data for said patient (step S2), and predicting with a trained Artificial Intelligence (Al) module the dependency Ci (pi) of the radiotherapy quality criterion Ci from the radiotherapy planning parameter p, when adjusting said radiotherapy planning parameter pi, thereby using the geometric patient data, the dose prescription data and the treatment indication data as input for the Al module (step S3).

Device for personalized radiotherapy using AI-controlled dosimetry, comprising: - a patient data acquisition unit configured to receive real-time data on patient-specific health information, including medical imaging data from the patient's CT, MRI and PET scans, biometric data from wearable or hospital-grade monitoring devices, electronic health records (EHRs) and previous treatment history; - The medical image processing unit, which analyzes and processes the captured image data, performs various functions, from tumor segmentation and identification of organs at risk to the spatial alignment of multimodal images for radiotherapy planning; - a CPU is configured to preprocess other collected data by (a) normalizing imaging and physiological data, (b) aggregating imaging and physiological data, (c) encoding imaging and physiological data for subsequent analysis, and (d) ensuring the compatibility and consistency of data from different sources; - an artificial intelligence (AI) controlled dosimetry machine that is communicatively connected to the central processing unit, wherein the AI-controlled dosimetry machine is configured to use machine learning algorithms to evaluate patient-specific parameters, optimize the distribution of a radiation dose and predict responses to treatment; - a visualization and treatment planning interface coupled with the AI-driven dosimetry machine, the visualization interface being configured to provide radiation dose distributions, patient-specific treatment recommendations, and comparative dose plans that enable data-driven adjustments by clinicians; and - a visualization interface with a feedback mechanism that allows real-time input from practicing clinicians and continuous automatic recording of patient response, which is used for iterative improvement of both the dosimetry model and the treatment plan.

Systems and methods for guiding radiation therapy including providing particle radiation to a region of interest of a subject and receiving volumetric ionizing radiation acoustic imaging (iRAI) data and ultrasound imaging data from the region of in response the particle radiation. Further, from the iRAI data and the ultrasound imaging, a position of the particle radiation in the region of interest is determined, that position being a treatment position of the particle radiation. Further, the systems and methods determine one or more parameters of the particle radiation for adjusting in response to the determination of the position.

The present application provides methods of treating cancer in a subject involving administering to the subject an SHP-1 inhibitor (e.g., TPI-1 or an analog or derivative thereof) and a pro-inflammatory agent (e.g., a TLR agonist, radiation therapy, or an immune checkpoint inhibitor). In some cases, the methods involve administering an SHP-1 inhibitor when the individual is in an inflammatory response.

Systems and methods are disclosed for analyzing data from oncology treatments such as immune checkpoint inhibitor or radiotherapy therapies, including predicting adverse events of the oncology therapies, predicting objective response of the oncology therapies, predicting symptoms from the oncology therapies, and use of such predictions by technological implementations to achieve improved system and medical outcomes. An example technique for generating a predicted treatment outcome includes: receiving patient data for a human subject, which provides patient-reported outcomes collected from the human subject relating to a particular oncology treatment; processing the patient data with a trained artificial intelligence (AI) prediction model, which receives the patient data as input and produces a prediction of a treatment outcome as output; and outputting data to modify a treatment workflow of an oncology treatment for the human subject, based on the prediction of the treatment outcome.

The invention provides radiation sensitive compositions and substrates coated with radiation sensitive compositions wherein the composition comprises a combination of metals and / or metalloid compounds, a functionalized or unfunctionalized acetylenic compound, and other optional ingredients such as amelioration agents. The invention further provides radiation sensitive devices for detection or measurement of radiation comprising substrates coated with these radiation sensitive compositions. The radiation sensitive compositions and devices have applications in dentistry, non-destructive testing, oncology, radiology, and radiotherapy, among others.

A method of generating an emulsion for treating a patient. The method includes generating a water-based solution carrying an agent which turns into a hydrogel by addition of calcium ions. Radium radionuclides are added to the water-based solution in a concentration sufficient for radiotherapy. After adding the radium to the water-based solution, the water-based solution is mixed with an emulsifier and an oil.

Treatment of Cancer Methods for treatment of cancer, in particular soft tissue sarcomas (STS), are described, as well as compounds, compositions, and combined preparations for use in such methods. An effective amount of: a LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; a programmed cell death protein-1 (PD-1) pathway inhibitor; and radiotherapy, is administered to a subject. Optionally the subject has undergone, is undergoing, or is to undergo, surgery for treatment of the cancer. A clinical trial study is described in which a triple combination of LAG-3 derivative eftilagimod alpha, a PD-1 pathway inhibitor, and radiotherapy was administered. The combination was surprisingly effective in the treatment of STS in patients who have completed 10 weeks of treatment, followed by surgery 2-3 weeks later. A substantial number of near complete pathological responses were observed, which are rarely seen in STS patients with standard therapeutic approaches including radiotherapy.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

According to one embodiment, a radiotherapy planning apparatus includes processing circuitry. The processing circuitry set irradiation conditions for a medical image relating to a patient. The processing circuitry acquires a histogram of a radiation dose rate in a predetermined area in the patient based on the irradiation conditions. The processing circuitry evaluates the irradiation conditions based on the histogram. The processing circuitry outputs information based on an evaluation result of the irradiation conditions.

The present disclosure relates to the field of radiation therapy and methods, software and systems for treatment planning.

Example methods and systems for kinematic calibration of a treatment couch for radiation therapy are described. In one example, a computer system may generate and send first instruction(s) to cause the treatment couch to move towards each of multiple calibration poses. The treatment couch may be associated with a kinematic model. The computer system may determine multiple measured poses that are associated with the respective multiple calibration poses. Next, the computer system may determine geometric correction data for updating the kinematic model based on the multiple measured poses. The computer system may then generate and send second instruction(s) to update the kinematic model associated with the treatment couch based on the geometric correction data.

Uterine cervical cancer radiotherapy support system for supporting combined intracavitary and interstitial brachytherapy for uterine cervical cancer includes support information obtaining means for obtaining patient support information to include base point serving as coordinate system base when capturing the patient's image before combined intracavitary and interstitial brachytherapy is performed, support information being at least any of the patient's image, drawn outline of tumor, drawn outline of organ surrounding tumor, drawn outline of needle insertion region, coordinates of center of gravity of needle insertion region, and dose distribution, and mixed reality displaying means for introducing virtual base point corresponding to base point and patient support information into virtual world, creating three-dimensional model of the patient, and displaying the three-dimensional model of the patient by overlaying it on the patient by matching the base point with the virtual base point with each other.

A method may include obtaining input data relating to a target treatment plan for performing radiotherapy on a lesion using a radiation device. The input data may include a first target image of the lesion. The method may also include obtaining a segment shape estimation model. The method may also include estimating, based on the segment shape estimation model and the input data, a plurality of target location combinations of the target treatment plan and a plurality of target segment shapes of a collimator of the radiation device. One of the plurality of target location combinations may indicate a location of the collimator relative to the lesion. Each of the plurality of target segment shapes may correspond to one of the plurality of target location combinations.

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

Provided are methods for treating cancer using local administration of certain CpG oligonucleotides (CpG ODN) and systemic administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and / or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-α) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Methods for treating a cancer patient with a neutrophil-to-lymphocyte ratio (NLR) greater than 3 are disclosed, comprising administering a nonsteroidal glucocorticoid receptor antagonist (GRA) to such a cancer patient, effective to reduce the patient's NLR. The methods include administering a nonsteroidal GRA and a cancer treatment to such a cancer patient, effective to reduce the patient's NLR and enhance the treatment of the cancer patient. The GRA may be orally administered. The nonsteroidal GRA may be a nonsteroidal compound comprising a heteroaryl ketone fused azadecalin structure (e.g., relacorilant) or an octahydro fused azadecalin structure (e.g., exicorilant). The cancer treatment may include chemotherapy, immunotherapy, radiation therapy, administration of an anti-angiogenic agent, administration of a growth factor inhibitor, and surgery. The methods may enhance the cancer treatment, improve the prognosis of the cancer patient, improve the survival of the cancer patient, and provide beneficial clinical effects and advantages to the patient.

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

A metal artifact reduction (MAR) method and system for reducing metal artifacts from X-ray images. The method is suitable for CT images generated with metallic elements exterior to a patient being scanned, for example, where external probes are applied to a patient, such as ultrasound probes. The method may be embodied in a computer algorithm for use, for example, in radiotherapy treatment planning and patient positioning procedures. In one application, the disclosed technique improves the dose delivery accuracy in ultrasound-guided cardiac radioablation, making this treatment modality a viable option for cardiac arrhythmias.

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

According to an aspect of the present disclosure, a beam control device for radiotherapy is provided. The beam control device may include an electron beam generator configured to emit an electron beam for radiotherapy toward a subject in a first direction. The beam control device may further include a first deflection device configured to generate a defocused electron beam by defocusing the electron beam in a second direction, the second direction being different from the first direction.

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

A method for treating liver cancer, in particular in subjects exhibiting homologous recombination deficiency (HRD) positive, comprises the use of hydroxyurea methyl acyl fulvene. The compounds may be administered as monotherapy or in combination with other chemotherapeutic agents and / or radiation therapy.

A system and method for generation and use of radiation outcome prediction (response & side effects) score for patients undergoing radiotherapy for various medical conditions wherein the score is a personalized score, provided by analyzing multiple parameters including the tumor specific, patient specific, gene specific and treatment planning specific parameter(s), during and post therapy.